News
IPA
--
0.00%
--
IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant
Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ:IPA) (TSXV:IPA) is pleased to share that IPA’s subsidiary Biostrand, a Belgian end-to-end multi-omics analysis
Benzinga · 05/09 12:22
ImmunoPrecise antibody cocktail shows neutralizing activity versus Omicron BA.2 in lab test
ImmunoPrecise Antibodies (NASDAQ:IPA) said its antibody cocktail PolyTope TATX-03 showed strong neutralizing activity against Omicron subvariant BA.2 in lab test. In-vitro data showed that the BA.2 pseudovirus was neutralized with a
Seekingalpha · 04/20 13:06
BRIEF-IPA Says Data On PolyTope TATX-03 Antibody Cocktail Shows Neutralizing Activity Toward Omicron BA.2
reuters.com · 04/20 12:25
WWR, CTXR and OTIC among pre market gainers
Clarus Therapeutics (CRXT) +18%. AlloVir (ALVR) +18% on FDA regenerative medicine tag for posoleucel to prevent 6 viruses in cell transplant patients. Westwater Resources (WWR) +15%  and Alabama Graphite Products break ground on
Seekingalpha · 04/20 12:19
ImmunoPrecise Antibodies Shares Spike Higher; Says Co's Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection Of Cells By Currently Dominant Omicron Sublineage BA.2, In Addition To All Other Variants Of Concern
IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of
Benzinga · 04/20 12:03
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
VICTORIA, British Columbia, April 20, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data on their PolyTope® TATX-03 antibody cocktail, which demonstrates st...
Business Wire · 04/20 12:01
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
VICTORIA, British Columbia, April 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, an...
Business Wire · 04/14 12:01
BRIEF-IPA Announces Deal To Buy BioStrand BV
reuters.com · 03/29 12:48
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
VICTORIA, British Columbia, March 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to acquire, through its wholly-ow...
Business Wire · 03/29 12:45
BRIEF-Immunoprecise Reports Financial Results For Q3 Fiscal Year 2022
reuters.com · 03/16 12:30
ImmunoPrecise Antibodies reports Q3 results
ImmunoPrecise Antibodies press release (NASDAQ:IPA): Q3 Net Loss of C$3.8M Revenue of C$4.8M (+6.4% Y/Y).
Seekingalpha · 03/16 12:06
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
VICTORIA, British Columbia, March 16, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for third quarte...
Business Wire · 03/16 12:02
Immunoprecise, Elektrofi To Pursue Low-Volume Injectable Formulation Of IPA's COVID-19 Antibody Cocktail
Benzinga · 03/14 16:40
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Benzinga · 03/13 21:37
Immunoprecise's COVID-19 Antibody Cocktail Shows Favorable Safety, Toxicity Profile
Immunoprecise Antibodies Ltd (NASDAQ: IPA) has reported preclinical data of PolyTope TATX-03 antibody cocktail therapy against COVID-19.
Benzinga · 03/09 17:41
IPA Updates On Investigational New Drug Enabling Program For PolyTope TATX-03
In vivo, IND enabling evaluations of PolyTope® TATX-03 in animal model show: There were no pharmacokinetic aberrations Injection with TATX-03 is well tolerated - with a significant safety margin and no
Benzinga · 03/09 13:16
IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03
VICTORIA, British Columbia, March 09, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company") (NASDAQ: IPA) (TSXV: IPA) is pleased to report on the latest progress in the development of their PolyTope® TATX-03 antibody cocktail therapy with a proven stro...
Business Wire · 03/09 13:01
ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET
VICTORIA, British Columbia, March 08, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced today announced that it will host ...
Business Wire · 03/08 13:01
Inspira, Genetron lead healthcare gainers; Amphastar, NRx Pharmaceuticals among losers
Gainers: Inspira Technologies Oxy (NASDAQ:IINN) +23%. Genetron (NASDAQ:GTH) +15%. HUTCHMED (China) (NASDAQ:HCM) +12%. ImmunoPrecise Antibodies (NASDAQ:IPA) +11%. IceCure Medical (NASDAQ:ICCM) +9%. Losers: Amphastar Pharmaceuticals (NASDAQ:AMPH) -11%. NRx P...
Seekingalpha · 01/31 15:03
ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron
Immunoprecise Antibodies Ltd (NASDAQ: IPA) has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail.
Benzinga · 01/31 13:43
Webull provides a variety of real-time IPA stock news. You can receive the latest news about Immunoprecise through multiple platforms. This information may help you make smarter investment decisions.
About IPA
ImmunoPrecise Antibodies Ltd. is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.